Graham Jackson

Medical University of South Carolina — United States

Medicine · Health Sciences

70h-index17.7kcitations488works6.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(265), Protein Degradation and Inhibitors(128), Cancer Treatment and Pharmacology(74), Hematopoietic Stem Cell Transplantation(49), Peptidase Inhibition and Analysis(46)

Publications488 total

Allergen labelling and precautionary allergen labelling
Edward Elgar Publishing eBooks·2025
Evaluating the Real-World Value of Daratumumab Addition to Multiple Myeloma Induction Therapy by Real-World Minimal Residual Disease Assessment and Extended Genetic Profiling
Clinical Lymphoma Myeloma & Leukemia·2025Open Access
Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA)  RADAR trial in newly diagnosed transplant eligible patients
Blood·2025
Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.
Blood·2025
Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings
Blood·2025
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform
HemaSphere·2025Open Access
Mechanisms underlying an enhanced navigation-based intervention to improve timely adjuvant radiotherapy in head and neck cancer: Secondary outcomes from the NDURE RCT.
JCO Oncology Practice·2025
The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
Leukemia & lymphoma/Leukemia and lymphoma·2025· 1 citedOpen Access
Barriers and Timely Postoperative Radiation Therapy in Head and Neck Cancer
JAMA Otolaryngology–Head & Neck Surgery·2025· 1 citedOpen Access
Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling
Blood·2025· 2 citedOpen Access
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology·2025· 12 citedOpen Access
Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
Blood·2024Open Access
Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial
Blood·2024Open Access
Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
Blood·2024Open Access
MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation
Blood·2024· 2 cited
Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
Blood·2024· 3 citedOpen Access
Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
Blood·2024· 1 citedOpen Access
IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
Blood·2024· 8 cited
Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
Blood·2024· 2 citedOpen Access
Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
Blood·2024Open Access
page 1 of 25Next →

Frequent Co-authors

Gareth J. Morgan(25), Faith E. Davies(24), Gordon Cook(18), Walter M. Gregory(16), Mark T. Drayson(13), Brian A. Walker(13), Roger G. Owen(11), Martin Kaiser(11), Fiona M. Ross(11), Sue Bell(10), J. Anthony Child(9), Hartmut Goldschmidt(9), Richard S. Houlston(9), Charlotte Pawlyn(7), Peter Broderick(7), Christopher P. Wardell(6), David C. Johnson(6), David A. Cairns(6), Nigel H. Russell(6), Hermann Einsele(6)